Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial - Eggermont, A MM; Chiarion-Sileni, V; Grob, J J (The Lancet Oncology, 2015)
. doi:10.1016/S1470-2045(15)70122-1